SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20: 3484-3494.
  • 2
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21: 3431-3439.
  • 3
    van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000; 18: 487-497.
  • 4
    van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994; 12: 312-325.
  • 5
    Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000; 18: 498-509.
  • 6
    Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002; 100: 1989-1996.
  • 7
    Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996; 14: 2435-2443.
  • 8
    Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002; 94: 182-192.
  • 9
    Travis LB, Curtis RE, Bennett WP, Hankey BF, Travis WD, Boice JD. Lung cancer after Hodgkin's disease. J Natl Cancer Inst. 1995; 87: 1324-1327.
  • 10
    Das P, Ng AK, Stevenson MA, Mauch PM. Clinical course of thoracic cancers in Hodgkin's disease survivors. Ann Oncol. 2005; 16: 793-797.
  • 11
    Laurie SA, Kris MG, Portlock CS, et al. The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease. Cancer. 2002; 95: 119-126.
  • 12
    Travis LB, Gilbert E. Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use. Radiat Res. 2005; 163: 695-696.
  • 13
    van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995; 87: 1530-1537.
  • 14
    Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res. 2003; 159: 161-173.
  • 15
    Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol. 2001; 19: 1610-1618.
  • 16
    Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol. 2005; 6: 773-779.
  • 17
    Curtis RE, Ries LG. Methods. In: Curtis RE, Freedman DM, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ. No. 05-5302. Bethesda, MD: National Cancer Institute; 2006: 9-14.
  • 18
    Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008; 26: 3937-3942.
  • 19
    Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010; 28: 5088-5096.
  • 20
    Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995; 1: 33-42.
  • 21
    Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002; 20: 2101-2108.
  • 22
    Behrens C, Travis LB, Wistuba II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev. 2000; 9: 1027-1035.
  • 23
    Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989; 73: 47-56.
  • 24
    Tubiana M, Henry-Amar M, Hayat M, et al. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. Int J Radiat Oncol Biol Phys. 1984; 10: 197-210.
  • 25
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83: 584-594.
  • 26
    Glaser SL. Regional variation in Hodgkin's disease incidence by histologic subtype in the US. Cancer. 1987; 60: 2841-2847.
  • 27
    Clarke CA, Glaser SL, Keegan TH, Stroup A. Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1441-1447.
  • 28
    Hu E, Hufford S, Lukes R, et al. Third-World Hodgkin's disease at Los Angeles County-University of Southern California Medical Center. J Clin Oncol. 1988; 6: 1285-1292.
  • 29
    Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin's disease in Los Angeles vary by cell type. Cancer Epidemiol Biomarkers Prev. 1992; 1: 261-268.
  • 30
    De Giacomo T, Martelli M, Venuta F, et al. Lung cancer after treatment for non-Hodgkin lymphoma. Minerva Chir. 2006; 61: 467-471.
  • 31
    Stinchcombe TE, Hodgson L, Herndon JE 2nd, et al. Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009; 4: 1117-1125.
  • 32
    Siddiqui F, Bae K, Langer CJ, et al. The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials. J Thorac Oncol. 2010; 5: 631-639.
  • 33
    Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008; 3: 457-466.
  • 34
    Ng AK, Abramson JS, Digumarthy SR, Reingold JS, Stone JR. Case records of the Massachusetts General Hospital. Case 24-2010: a 56-year-old woman with a history of Hodgkin's lymphoma and sudden onset of dyspnea and shock. N Engl J Med. 2010; 363: 664-675.
  • 35
    Das P, Ng AK, Earle CC, Mauch PM, Kuntz KM. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol. 2006; 17: 785-793.
  • 36
    Hudson MM, Landier W, Constine LS, et al. Children's Oncology Group long-term follow-up guidelines. http://www.childrensoncologygroup.org/disc/LE/pdf/LTFUGuidelines.pdf. [Access date,] 2010.
  • 37
    National Lung Screening Trial Research Team; Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011; 258: 243-253.
  • 38
    Aberle DR, Adams AM, Berg CD, et al. Baseline characteristics of participants in the randomized National Lung Screening Trial. J Natl Cancer Inst. 2010; 102: 1771-1779.
  • 39
    National Cancer Institute. National Lung Screening Trial (NLST). http://www.cancer.gov/clinicaltrials/noteworthy-trials/nlst. Accessed December 30, 2010.
  • 40
    Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007; 357: 2277-2284.
  • 41
    US National Institutes of Health. National Clinical Trial 00601146. http://clinicaltrials.gov/ct2/show/NCT00601146. Accessed December 30, 2010.